bemarituzumab   Click here for help

GtoPdb Ligand ID: 11278

Synonyms: FPA-144 | FPA144
Compound class: Antibody
Comment: Bemarituzumab (FPA144) is first-in-class anti-fibroblast growth factor receptor 2b (FGFR2b) chemotherapy antibody from Five Prime Therapeutics [2]. It is humanized and of the immunoglobulin G1 (IgG1) isotype. It binds to FGFR2b and promotes ADCC via enhanced binding to FcγRIIIa. Bemarituzumab is designed to target FGFR2b on cancer cells that use the FGF/FGFR pathway to promote transformation, proliferation and angiogenesis.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
10681 bemarituzumab
Synonyms Click here for help
FPA-144 | FPA144
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 770
Other databases
GtoPdb PubChem SID 434321713
Search PubMed clinical trials bemarituzumab
Search PubMed titles bemarituzumab
Search PubMed titles/abstracts bemarituzumab